| P/E (FY) | 7.9 | Sales (TTM) | $676.8M |
| Earnings (TTM) | -$8.6M | ROE | 10.46% |
| Net Margin | 7.08% | ROIC | 6.57% |
| Debt / Equity | 1.09 | TD / EBITDA | 2.92 |
| EPS Growth 3Y | — | Sales Growth 3Y | −12.72% |
Emergent BioSolutions is a life sciences company providing preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. Its portfolio includes the ACAM2000 smallpox and mpox vaccine, anthrax products such as ANTHRASIL, BioThrax, and CYFENDUS, botulism antitoxin BAT, the Ebola treatment Ebanga, and Raxibacumab.
| Market Cap | $377.2M | Trading Days | 2523 |
| 52W High | 14.06 |
| 52W Low | 5.62 |
| % Off High | −48.01% |
| YTD | −40.86% | 1Y | 7.82% |
| 3Y | 7.82% | 5Y | −88.78% |
| 10Y | −76.44% | Since incept. (ann.) | −12.75% |
US 71% · Other Geographical Area 18% · CA 10%
| Ann. Volatility (1Y) | 81.70% | Ann. Volatility (3Y) | 118.08% |
| Sharpe (1Y) | 0.48 | Sharpe (3Y) | 0.55 |
| Max Drawdown (1Y) | −47.77% | Max Drawdown (3Y) | −81.04% |
| Beta (3Y, vs SPY) | 4.61 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CAPR | CAPRICOR THERAPEUTICS, INC. | $380.5M | — |
| KROS | Keros Therapeutics, Inc. | $381.2M | 4.4 |
| PRLD | Prelude Therapeutics Inc | $369.6M | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $366.7M | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $364.7M | 19.6 |
| AVIR | Atea Pharmaceuticals, Inc. | $360.9M | — |
| DMAC | DiaMedica Therapeutics Inc. | $357.8M | — |
| LRMR | Larimar Therapeutics, Inc. | $397.9M | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $403.9M | 12.5 |
| EVMN | Evommune, Inc. | $405.2M | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $405.7M |
| 13.1 |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $406.4M | — |
